Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators - PubMed (original) (raw)
. 1998 Mar 26;338(13):853-60.
doi: 10.1056/NEJM199803263381301.
Affiliations
- PMID: 9516219
- DOI: 10.1056/NEJM199803263381301
Free article
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
F J Palella Jr et al. N Engl J Med. 1998.
Free article
Abstract
Background and methods: National surveillance data show recent, marked reductions in morbidity and mortality associated with the acquired immunodeficiency syndrome (AIDS). To evaluate these declines, we analyzed data on 1255 patients, each of whom had at least one CD4+ count below 100 cells per cubic millimeter, who were seen at nine clinics specializing in the treatment of human immunodeficiency virus (HIV) infection in eight U.S. cities from January 1994 through June 1997.
Results: Mortality among the patients declined from 29.4 per 100 person-years in the first quarter of 1995 to 8.8 per 100 in the second quarter of 1997. There were reductions in mortality regardless of sex, race, age, and risk factors for transmission of HIV. The incidence of any of three major opportunistic infections (Pneumocystis carinii pneumonia, Mycobacterium avium complex disease, and cytomegalovirus retinitis) declined from 21.9 per 100 person-years in 1994 to 3.7 per 100 person-years by mid-1997. In a failure-rate model, increases in the intensity of antiretroviral therapy (classified as none, monotherapy, combination therapy without a protease inhibitor, and combination therapy with a protease inhibitor) were associated with stepwise reductions in morbidity and mortality. Combination antiretroviral therapy was associated with the most benefit; the inclusion of protease inhibitors in such regimens conferred additional benefit. Patients with private insurance were more often prescribed protease inhibitors and had lower mortality rates than those insured by Medicare or Medicaid.
Conclusions: The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.
Comment in
- Progress and problems in the fight against AIDS.
Hirschel B, Francioli P. Hirschel B, et al. N Engl J Med. 1998 Mar 26;338(13):906-8. doi: 10.1056/NEJM199803263381310. N Engl J Med. 1998. PMID: 9516228 - Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.
Michaels SH, Clark R, Kissinger P. Michaels SH, et al. N Engl J Med. 1998 Aug 6;339(6):405-6. doi: 10.1056/NEJM199808063390612. N Engl J Med. 1998. PMID: 9696654 No abstract available. - AIDS among heterosexuals in surveillance reports.
Haverkos HW, Chung RC. Haverkos HW, et al. N Engl J Med. 2001 Feb 22;344(8):611-3. doi: 10.1056/nejm200102223440815. N Engl J Med. 2001. PMID: 11221631 No abstract available.
Similar articles
- Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
Jones JL, Hanson DL, Dworkin MS, Alderton DL, Fleming PL, Kaplan JE, Ward J. Jones JL, et al. MMWR CDC Surveill Summ. 1999 Apr 16;48(2):1-22. MMWR CDC Surveill Summ. 1999. PMID: 12412613 - Changes in AIDS-defining illnesses in a London Clinic, 1987-1998.
Mocroft A, Sabin CA, Youle M, Madge S, Tyrer M, Devereux H, Deayton J, Dykhoff A, Lipman MC, Phillips AN, Johnson MA. Mocroft A, et al. J Acquir Immune Defic Syndr. 1999 Aug 15;21(5):401-7. J Acquir Immune Defic Syndr. 1999. PMID: 10458621 - The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ, Gazzard BG, Easterbrook PJ. Ives NJ, et al. J Infect. 2001 Feb;42(2):134-9. doi: 10.1053/jinf.2001.0810. J Infect. 2001. PMID: 11531320 - [Clinical impact of combination antiretroviral therapy].
Gatanaga H. Gatanaga H. Nihon Rinsho. 2002 Apr;60(4):739-44. Nihon Rinsho. 2002. PMID: 11968781 Review. Japanese. - Pulmonary infections in children with HIV infection.
Pérez Mato S, Van Dyke RB. Pérez Mato S, et al. Semin Respir Infect. 2002 Mar;17(1):33-46. doi: 10.1053/srin.2002.31685. Semin Respir Infect. 2002. PMID: 11891517 Review.
Cited by
- The role of HIV as an independent risk factor to cervical HSIL recurrence.
Fonseca FV, de Carvalho NS, Maestri CA, Martins MF, Kowacs DP. Fonseca FV, et al. Rev Bras Ginecol Obstet. 2024 Oct 23;46:e-rbgo85. doi: 10.61622/rbgo/2024rbgo85. eCollection 2024. Rev Bras Ginecol Obstet. 2024. PMID: 39530067 Free PMC article. - Fasting plasma glucose trends in the elderly living with HIV/AIDS on combination antiretroviral therapy regimens.
Shang M, Zhang J, Chen M, Chen X, Liu C, Zhong H, Du P, Li Q, Cai W, Li L, Gu J. Shang M, et al. BMJ Open. 2024 Nov 4;14(11):e085266. doi: 10.1136/bmjopen-2024-085266. BMJ Open. 2024. PMID: 39496366 Free PMC article. - Analyzing Social Support from Facebook on Viral Suppression among Young Black Men Who Have Sex with Men Living with HIV: A Pilot Study.
Friedman EE, Del Vecchio N, Mason JA, Devlin SA, Ridgway JP, Schneider JA. Friedman EE, et al. Int J Environ Res Public Health. 2024 Oct 12;21(10):1352. doi: 10.3390/ijerph21101352. Int J Environ Res Public Health. 2024. PMID: 39457325 Free PMC article. - Drug-Related Problems in HIV Treatment Failure.
Che Pa MF, Tiang Koi N, Misnan A, Islahudin FH, Makmor-Bakry M. Che Pa MF, et al. Cureus. 2024 Sep 21;16(9):e69838. doi: 10.7759/cureus.69838. eCollection 2024 Sep. Cureus. 2024. PMID: 39435225 Free PMC article. - Transmitted drug resistance and molecular transmission network among treatment-naive HIV-1 patients in Wenzhou, China, 2020-2023.
Zhang T, Dou H, Ye H, Tang H, Wang W, Hu W, Lv B, Zhou M, Dai H, Wang W, Sun B. Zhang T, et al. Virol J. 2024 Oct 17;21(1):257. doi: 10.1186/s12985-024-02528-2. Virol J. 2024. PMID: 39420358 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials